Enteric Nervous System Prion-Like Propagation Blockade
Target: TLR4, SNCA
Composite Score: 0.480
Price: $0.48▲6.5%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Evidence Strength
Pending (0%)
24
Citations
1
Debates
5
Supporting
2
Opposing
Quality Report Card click to collapse
C
Composite: 0.480
Top 79% of 1510 hypotheses
T1 Established
Multi-source converged and validated
T0 Axiom requires manual override only
C
0.40
Top 91%
C+
0.50
Top 64%
B+
0.70
Top 45%
D
0.30
Top 91%
B
0.60
Top 64%
B
0.60
Top 45%
C
0.40
Top 83%
C+
0.50
Top 82%
C
0.40
Top 88%
C
0.40
Top 83%
Evidence
5 supporting
|
2 opposing
Citation quality: 100%
Debates
1 session
A
Avg quality: 0.89
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
Description
Dysbiotic bacteria produce lipopolysaccharides that enhance α-synuclein prion-like propagation from enteric neurons to the CNS via the vagus nerve. Targeted antimicrobial therapy against specific pathogenic strains could interrupt this ascending pathological cascade.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Dysbiotic Gut
Microbiome"] --> B["Bacterial LPS
Production"]
B --> C["TLR4 Activation
on Enteric Neurons"]
C --> D["MyD88 and TRIF
Recruitment"]
D --> E["NF-kappaB and IRF3
Signaling"]
E --> F["Pro-inflammatory
Cytokine Release
(IL-1beta, TNF-alpha)"]
F --> G["Neuroinflammation
in ENS"]
G --> H["Enhanced alpha-Synuclein
Aggregation"]
H --> I["Prion-like
alpha-Synuclein
Formation"]
I --> J["Cell-to-Cell
Transmission
in ENS"]
J --> K["Vagus Nerve
Propagation"]
K --> L["CNS alpha-Synuclein
Pathology"]
L --> M["Neurodegeneration"]
N["TLR4 Antagonists"] -->|"Therapeutic
Blockade"| C
O["Microbiome
Restoration"] -->|"Therapeutic
Intervention"| A
P["Vagotomy"] -->|"Surgical
Intervention"| K
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B pathology
class C,D,E,F,G,H,I,J,K molecular
class L,M outcome
class N,O,P therapeutic
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations
7 with PMID
7 medium
Validation: 100%
5 supporting / 2 opposing
✓
For
(5)
(2)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 4CLIN 3GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 5
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. MEDIUM
Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atr… MEDIUM▼
Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.
Targeted degradation of SNCA/α-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform. MEDIUM
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. MEDIUM
Neuronal activity triggers secretory autophagy to mediate the extracellular release of SNCA/α-synuclein. MEDIUM
✗ Opposing Evidence 2
The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to c… MEDIUM▼
The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to causal human intervention evidence.
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and cl… MEDIUM▼
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and clinical efficacy questions.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 6 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Based on the provided literature on the gut-brain axis and Parkinson's disease, here are 7 novel therapeutic hypotheses:
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Description: Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.
Target gene/protein: SNCA (α-synuclein), HSPA1A (HSP70), DNMT1
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and gaps in the evidence.
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Critical Weaknesses:
- Mechanistic gap: No direct evidence that SCFAs can disaggregate α-synuclein in vivo. The leap from "SCFAs affect epigenetics" to "SCFAs disaggregate α-synuclein" lacks mechanistic validation.
- Blood-brain barrier assumptions: While some SCFAs cross the BBB, their concentrations and stability in brain tissue remain poorly characterized.
- Chaperone specificity: No evidence that SCFA-medi
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
REFINED DRUG DEVELOPMENT FEASIBILITY ASSESSMENT
Based on the additional data retrieved, I'm updating my feasibility rankings with concrete evidence from current research and clinical pipelines.
UPDATED HYPOTHESIS RANKINGS
1. NLRP3 Inflammasome Inhibition (Hypothesis #6)
Feasibility Score: 8/10 ⬆️ Upgraded based on new clinical dataKey Development Update:
- NT-0796 (PMID:40792655, 2025) showing anti-neuroinflammatory effects specifically in PD subjects
- KPT-8602 (PMID:35721113) demonstrating NF-κB/NLRP3 pathway inhibition in PD models
**Immediate Opportunities:
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↘
Falling
7d Momentum
▼ 28.5%
Volatility
High
0.0602
Events (7d)
7
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| ⚖ | Recalibrated | $0.480 | ▲ 3.1% | calibrate_stale_price_his | 2026-04-26 13:47 |
| 📄 | New Evidence | $0.465 | ▲ 1.6% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.458 | ▲ 4.1% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.440 | ▼ 0.5% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.442 | ▼ 1.3% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.448 | ▲ 1.5% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.441 | ▼ 3.8% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.459 | ▼ 13.1% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.528 | ▼ 0.6% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.531 | ▼ 0.8% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.536 | ▲ 1.1% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.530 | ▼ 4.1% | 2026-04-03 23:46 | |
| ⚖ | Recalibrated | $0.552 | ▼ 5.2% | 2026-04-02 21:55 | |
| 💬 | Debate Round | $0.582 | ▲ 36.8% | market_dynamics | 2026-04-02 20:14 |
| ⚖ | Recalibrated | $0.426 | ▼ 3.4% | market_recalibrate | 2026-04-02 19:14 |
Clinical Trials (5) Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALS
PHASE2
RECRUITING
·
NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED
·
NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN
·
NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
PHASE1
NOT_YET_RECRUITING
·
NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED
·
NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
📚 Cited Papers (43)
The potential of Diosgenin in treating psoriasis: Studies from HaCaT keratinocytes and imiquimod-induced murine model.
Life sciences (2020) · PMID:31790685
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice.
Scientific reports (2019) · PMID:30962497
9 figures
Figure 1
Illustration of the protocols, including the time line of the experiments and tests.
pmc_api
Figure 2
LPS-induced memory defects in the MWM test and passive avoidance performance test. ( A ) Mice showed impaired learning and memory function after injections of LPS during the place-...
pmc_api
Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration.
Nat Commun (2020) · PMID:32170061
7 figures
Fig. 1
Neuron-released α-synuclein is engulfed by microglia in vivo. a , b , f , g Brain sections from AAV-GFP ( n = 768 cells, six animals) and AAV- h α-Syn-injected mice ( n = 986...
pmc_api
Fig. 2
Microglia-engulfed α-synuclein is degraded by autophagy. a , b , c Cultured primary microglia from WT mice ( a and left panels of b ) and GFP–LC3-transgenic mice (right panels...
pmc_api
Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets.
International journal of molecular sciences (2025) · PMID:41465422
5 figures
Figure 1
Hypothesis of microglial polarization from the M2 to M1 phenotype and NLRP3 inflammasome activation. Panel ( A ) In the APP/PS1 mouse model of Alzheimer’s disease, microglia initia...
pmc_api
Figure 2
Hypothesis of crosstalk among microglia, astrocytes, and neurons. Panel schematic on the ( right ). An M1 polarized microglial cell releases proinflammatory mediators that act on A...
pmc_api
Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Cancer chemotherapy and pharmacology (2017) · PMID:28011980
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
The international journal of neuropsychopharmacology (2014) · PMID:25522431
No extracted figures yet
Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Cancer chemotherapy and pharmacology (2017) · PMID:28011980
No extracted figures yet
RETRACTED: Hesperetin, a Citrus Flavonoid, Attenuates LPS-Induced Neuroinflammation, Apoptosis and Memory Impairments by Modulating TLR4/NF-κB Signaling.
Nutrients (2019) · PMID:30884890
No extracted figures yet
Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice.
Scientific reports (2019) · PMID:30962497
No extracted figures yet
TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Acta pharmacologica Sinica (2019) · PMID:31388087
No extracted figures yet
The potential of Diosgenin in treating psoriasis: Studies from HaCaT keratinocytes and imiquimod-induced murine model.
Life sciences (2020) · PMID:31790685
No extracted figures yet
Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation.
Neurobiology of disease (2020) · PMID:32087283
No extracted figures yet
📙 Related Wiki Pages (15)
PBKR03 entityMYO6 — Myosin VI geneSNCA — Alpha-Synuclein geneToll-Like Receptor 4 (TLR4) proteinTLR4 Gene geneSNCA — Alpha-Synuclein Gene Entity Page geneLiquid Biopsy in Neurodegeneration biomarkerNeuroimaging Biomarkers for Neurodegeneration biomarkerSynaptic Biomarkers in Neurodegeneration biomarkerExosomal Biomarkers in Neurodegeneration biomarkerIL-6 (Interleukin-6) in Neurodegeneration biomarkerCSF Neurofilament Light Chain (NfL) in Neurodegene biomarkerDNA Methylation Biomarkers in Neurodegeneration biomarkerBlood-Based Biomarkers for Neurodegeneration biomarkerExosomal miR-155 in Neurodegeneration biomarker
📓 Linked Notebooks (5)
📓 SciDEX Analysis: 2026 04 01 Gap 20260401 225155
Computational notebook for SDA-2026-04-01-gap-20260401-225155
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influ …
📓 Gut microbiome dysbiosis and Parkinsons disease -- Rich Analysis Notebook
Gene expression, pathway enrichment, statistical tests for: Gut microbiome dysbiosis and Parkinsons disease
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📊 Resource Economics & ROI
Low Efficiency
Resource Efficiency Score
0.49
24.2th percentile (747 hypotheses)
Tokens Used
20,466
KG Edges Generated
15
Citations Produced
24
Cost Ratios
Cost per KG Edge
40.53 tokens
Lower is better (baseline: 2000)
Cost per Citation
1137.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
38040.89 tokens
Tokens / composite_score
Score Impact
Efficiency Boost to Composite
+0.049
10% weight of efficiency score
Adjusted Composite
0.529
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Efficiency Price Signals
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-16T20:00 | $0.456 | 0.580 |
Wiki Pages
PBKR03entityMYO6 — Myosin VIgeneSNCA — Alpha-SynucleingeneToll-Like Receptor 4 (TLR4)proteinTLR4 GenegeneSNCA — Alpha-Synuclein Gene Entity PagegeneLiquid Biopsy in NeurodegenerationbiomarkerNeuroimaging Biomarkers for NeurodegenerationbiomarkerSynaptic Biomarkers in NeurodegenerationbiomarkerExosomal Biomarkers in NeurodegenerationbiomarkerIL-6 (Interleukin-6) in NeurodegenerationbiomarkerCSF Neurofilament Light Chain (NfL) in NeurodegenebiomarkerDNA Methylation Biomarkers in NeurodegenerationbiomarkerBlood-Based Biomarkers for NeurodegenerationbiomarkerExosomal miR-155 in Neurodegenerationbiomarker
KG Entities (12)
GLP1_receptorNLRP3Parkinsons_diseaseSCFA_productionblood_brain_barriergut_microbiomeinflammasome_complexintestinal_barrierneuroinflammation_pathwayneuroprotectiontight_junction_proteinsvagal_signaling_pathway
Dependency Graph (3 upstream, 5 downstream)
Depends On
Cross-Seeding Prevention Strategybuilds_on (1.0)Smartphone-Detected Motor Variability Correctionbuilds_on (1.0)Noradrenergic-Tau Propagation Blockadebuilds_on (0.8)Depended On By
Microbiome-Derived Tryptophan Metabolite Neuroprotectionbuilds_on (1.0)Gut Barrier Permeability-α-Synuclein Axis Modulationbuilds_on (1.0)Microbial Metabolite-Mediated α-Synuclein Disaggregationbuilds_on (1.0)Vagal Afferent Microbial Signal Modulationbuilds_on (1.0)Microbial Inflammasome Priming Preventionbuilds_on (1.0)Linked Experiments (10)
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleationvalidation | tests | 0.40Iron Dyshomeostasis in MSA Pathogenesis Experimentvalidation | tests | 0.40Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanismsclinical | tests | 0.40Microbiome-Gut Barrier Signatures in ALS — Experiment Designclinical | tests | 0.40Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Interventionclinical | tests | 0.40Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagationclinical | tests | 0.40Tau Co-Pathology in DLB Clinical Heterogeneityclinical | tests | 0.40SCFA-Mediated Neuroinflammation in Alzheimer's Diseaseclinical | tests | 0.40Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progressclinical | tests | 0.40Parkinson's Disease Subtype Classification — Precision Medicine Approachclinical | tests | 0.40
Related Hypotheses
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
CYP46A1 Overexpression Gene Therapy
Score: 0.950 | neurodegeneration
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.948 | neurodegeneration
SASP-Mediated Complement Cascade Amplification
Score: 0.947 | neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.937 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.4 years
🧪 Falsifiable Predictions (3)
3 total
0 confirmed
0 falsified
If hypothesis is true, intervention be essential for patient stratification and treatment monitoring
pending
conf: 0.50
Expected outcome: be essential for patient stratification and treatment monitoring
Falsified by: Intervention fails to be essential for patient stratification and treatment monitoring
If hypothesis is true, intervention be therapeutically targeted across multiple neurodegenerative conditions
pending
conf: 0.50
Expected outcome: be therapeutically targeted across multiple neurodegenerative conditions
Falsified by: Intervention fails to be therapeutically targeted across multiple neurodegenerative conditions
If hypothesis is true, intervention provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
pending
conf: 0.50
Expected outcome: provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
Falsified by: Intervention fails to provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
Knowledge Subgraph (7 edges)
associated with (2)
contributes to (1)
encodes component (1)
maintains (1)
mediates (1)
promotes (1)
Mechanism Pathway for TLR4, SNCA
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
NLRP3["NLRP3"] -->|encodes component| inflammasome_complex["inflammasome_complex"]
neuroinflammation_pathway["neuroinflammation_pathway"] -->|contributes to| Parkinsons_disease["Parkinsons_disease"]
GLP1_receptor["GLP1_receptor"] -->|mediates| vagal_signaling_pathway["vagal_signaling_pathway"]
vagal_signaling_pathway_1["vagal_signaling_pathway"] -->|promotes| neuroprotection["neuroprotection"]
tight_junction_proteins["tight_junction_proteins"] -->|maintains| intestinal_barrier["intestinal_barrier"]
gut_microbiome["gut_microbiome"] -->|associated with| SCFA_production["SCFA_production"]
SCFA_production_2["SCFA_production"] -->|associated with| blood_brain_barrier["blood_brain_barrier"]
style NLRP3 fill:#ce93d8,stroke:#333,color:#000
style inflammasome_complex fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation_pathway fill:#81c784,stroke:#333,color:#000
style Parkinsons_disease fill:#ef5350,stroke:#333,color:#000
style GLP1_receptor fill:#4fc3f7,stroke:#333,color:#000
style vagal_signaling_pathway fill:#81c784,stroke:#333,color:#000
style vagal_signaling_pathway_1 fill:#81c784,stroke:#333,color:#000
style neuroprotection fill:#ffd54f,stroke:#333,color:#000
style tight_junction_proteins fill:#4fc3f7,stroke:#333,color:#000
style intestinal_barrier fill:#4fc3f7,stroke:#333,color:#000
style gut_microbiome fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production_2 fill:#4fc3f7,stroke:#333,color:#000
style blood_brain_barrier fill:#4fc3f7,stroke:#333,color:#000
3D Protein Structure
🧬 TLR4 — PDB 3FXI Click to expand 3D viewer
Source Analysis
What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
Same Analysis (5)
Microbial Inflammasome Priming Prevention
Score: 0.65 · NLRP3, CASP1, IL1B, PYCARD
Vagal Afferent Microbial Signal Modulation
Score: 0.62 · GLP1R, BDNF
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.53 · CLDN1, OCLN, ZO1, MLCK
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51 · SNCA, HSPA1A, DNMT1
Microbiome-Derived Tryptophan Metabolite Neuroprotection
→ View all analysis hypotheses
Score: 0.43 · AHR, IL10, TGFB1